rates for all stages of prostate cancer are 92%. However, health care providers remain divided with regards to the best treatment for localized prostate cancer. With no definitive agreement regarding optimal therapy, diagnosed men experience heightened illness uncertainty related to treatment decision making (Bailey, Wallace, & Mishel, in press ).
Because of the widespread adoption of prostate specific antigen (PSA) screening, a high proportion of prostate cancer diagnoses are now made when tumors are nonpalpable and localized to the prostate gland. In addition, 10 years or more may elapse before progression to clinical symptoms occurs with prostate cancer (Draisma et al., 2003; Wilt & Partin, 2003) . This early detection has led to an increase in the reported incidence of the disease (Klotz, 2005a) and possibly to overtreatment of men with indolent tumors.
The issue of overtreatment is significant because all available therapeutic modalities for localized prostate cancer (radical prostatectomy, external beam radiotherapy, brachytherapy, and cryotherapy) entail significant risk of adverse effects such as sexual dysfunction, urethral strictures, urinary incontinence, or bowel problems (Wilt & Partin, 2003) , which can markedly decrease a patient's quality of life (Harlan P rostate cancer is the most commonly diagnosed cancer and the second-leading cause of death from cancer in U.S. men (Chan, Jou, & Carroll, 2004; Wilt & Partin, 2003) . The average age of men diagnosed with prostate cancer is between 72 and 74 years, and 85% of all prostate cancers are diagnosed in men older than 65 years. Less than 1% of men younger than 50 years of age are diagnosed with this disease (Gronberg, 2003) . In 2006, 234,460 new cases of prostate cancer are projected to occur (American Cancer Society, 2006 Prostate cancer is the most commonly diagnosed cancer and the second-leading cause of death from cancer in U.S. men. For older men with early-stage prostate cancer, watchful waiting (also referred to as surveillance, expectant management, deferred/delayed therapy, or active monitoring) is a reasonable approach to aggressive therapy. The purpose of this article is to critically review published studies on the watchful waiting management option for prostate cancer within the past 5 years. The review of documented reports on watchful waiting reveals that there are both negative and positive indications toward watchful waiting. Further research is needed to change the perception of watchful waiting as a "do nothing" approach to the management of prostate cancer or a "death sentence" and to develop interventions that assist men to manage the uncertainty associated with living with prostate cancer to improve health and advance quality of life. Keywords: prostate cancer; watchful waiting; illness uncertainty; men's health; expectant management Yao & Lu-Yao, 2002) . For older men with early-stage prostate cancer, watchful waiting (also referred to as surveillance, expectant management, deferred/delayed therapy, or active evaluating) is a reasonable approach to aggressive therapy. Prostate cancer patients undergoing watchful waiting attempt to circumvent the undesirable side effects commonly associated with treatments such as surgery or radiation therapy. Although some patients and health care providers believe that watchful waiting is analogous with doing nothing, Adolfsson (1995) defined watchful waiting as surveillance followed by active treatment if and when disease progression leads to troublesome symptoms. Recently, Parker (2004) offered a distinction between watchful waiting and active surveillance. He proposed that active surveillance aims to identify only those men with prostate tumors in need of medical intervention, and although these approaches differ in the timing of medical intervention, both recommend the careful evaluating and monitoring of patients. Watchful waiting generally involves reevaluation of symptoms, PSA, and tumor growth every 3 months for the 1st year. After the 1st year, follow-up appointments decrease to every 6 to 12 months if progression is stable. If tumor progression is evident, the tumor is likely then to be restaged via transrectal ultrasound-guided biopsies.
Previously, a man underwent watchful waiting with the expectation that he would likely die from causes other than prostate cancer. Today, men make the decision to actively evaluate their disease in conjunction with their health care providers with the knowledge that treatment remains an option (Wallace, Bailey, O'Rourke, & Galbraith, 2004) .
The Prostate Cancer Intervention Versus Observation Trial, begun in 1994, completed enrollment of 731 men as of January 30, 2002, and will continue to follow these men through 2009 to determine whether expectant management or treatment is the best option for localized prostate cancer (Debra McKeehen, personal communication, June 27, 2006) . Given the wide discontent with the morbidity associated with more aggressive treatments and the lack of evidence that one treatment has better morbidity or mortality rates than another, the trial may provide the data to support the election of watchful waiting by greater numbers of men in the future. However, it will be important to carefully evaluate and counsel men deemed suitable for this management option.
Previously, a group of men who were appropriate for watchful waiting was identified (Wallace et al., 2004) . These men had a life expectancy of 10 years or less, Gleason scores greater than 7, low PSA density and velocity, and organ-confined disease. Recent research by Warlick, Allaf, and Carter (2006) has refined the identification process to include men who are 65 years and older with T1c stage disease, PSA density < 0.15 ng/mL/cm 3 , and a Gleason grade of ≤6 following adequate biopsy as the safest candidates for a watchful waiting protocol followed by active treatment (Warlick et al., 2006) . By identifying appropriate patients for careful monitoring, and timely treatment if needed, these health care providers believe they will be able to expand eligibility criteria to include younger men who wish to preserve their quality of life (Warlick et al., 2006) .
Older men who have elected watchful waiting as their treatment option live every day with the knowledge that they have cancer in their bodies. Uncertainty about the state of cancer intensifies when men are asymptomatic or experience only occasional signs that the cancer is present. Men who experience no physical discomfort find it hard to believe that cancer exists. Without markers to indicate disease symptomatology, men may incorrectly attribute physical changes associated with aging to disease progression (Bailey et al., in press) .
The option of watchful waiting represents an almost unprecedented approach in American medicine because it defies the beliefs of physicians and patients who want to fight cancer with the best treatments available (Maxwell, 1993; Whitmore, 1993) . If watchful waiting is to succeed, health care providers must be able to correctly identify eligible men, that is, those patients whose "disease is destined to be an incidental histological phenomenon" (Hardie et al., 2005, p. 956) . Furthermore, patients must be offered appropriate support as they seek to manage the inevitable and constant uncertainty about their disease. Inability to do so may cause patients to deteriorate emotionally or to undergo aggressive intervention (Koppie et al., 2000; Patel et al., 2004) . This article critically reviews the current literature on watchful waiting for prostate cancer and evaluates the management option in light of available evidence.
Review of Literature
As a management option for prostate cancer, watchful waiting has been discussed extensively within the past 5 years (summarized in Table 1 ). Several prevalent themes are demonstrated in the literature on To explore the problems and uncertainties of older men with prostate cancer who have undergone watchful waiting and the strategies they use to manage their concerns.
To test the benefits of an intervention to enable 39 men with prostate cancer who underwent watchful waiting to manage the uncertainty associated with the disease and to help them to view their lives more positively, as well as improve their quality of life.
To estimate the 10-year survival rates of men assigned to watchful waiting or radical prostatectomy.
To describe how men chose watchful waiting instead of active treatment for prostate cancer.
To describe and compare the outcomes of men undergoing active surveillance or watchful waiting.
To describe trends in the use of watchful waiting and identify the characteristics of men undergoing this management option.
To highlight the meaning of living with prostate cancer that was not being treated.
Results
Mortality rate was 33 men per 1,000 person-year at 15 years and 18 deaths per 1,000 person-years for men after 15 years. Mortality in this study was linked with higher grade prostate cancers within 10 years of diagnosis. No significant increase in mortality was observed in men undergoing watchful waiting after the 15-year mark.
Domains of uncertainty, appraisal of danger, and appraisal of opportunity were identified, and each was supported by participant's experience.
Participants who received the intervention came to see their lives in a new light and reduced their depressive symptoms; they reported their quality of life as higher now and anticipated it being high in the future.
At 8.2 years of follow-up, there was a significant increase in mortality among men undergoing watchful waiting, with a relative increase in risk related to time with the disease.
Four men (8%) selected watchful waiting. Men reported considerable pressure from their families and support group members to pursue aggressive treatment.
At 42 months, 64 men were still in active surveillance, and 20 were still in watchful waiting.
The use of watchful waiting increased by 2% between the years of 1989 and 1994 but decreased 4% between 1994 and 2000 to an overall rate of 5.5% for all prostate cancer patients. Men undergoing watchful waiting were likely to have a low risk of morbidity and mortality from prostate cancer and were 75 years of age and older, White, less educated, and single. Medicare was their primary form of insurance, and they reported several comorbidities.
Living with untreated prostate cancer is like living life under a dark shadow. To compare survival between men with newly diagnosed prostate cancer randomly assigned to watchful waiting versus radical prostatectomy.
To describe PSA DT in men with localized prostate cancer undergoing active surveillance with delayed treatment.
To describe demographic and clinical characteristics of men undergoing watchful waiting.
To explore and describe newly diagnosed men's perceptions of undergoing watchful waiting.
To evaluate the use of expectant management with delayed intervention until disease progression in men with localized disease.
To determine if racial/ethnic differences exist in men undergoing watchful waiting relative to their risk for the disease.
To describe symptoms and quality of life in men with localized prostate cancer, randomized to watchful waiting or radical prostatectomy.
At 6.2-year follow-up, there was a significant difference in prostate cancer mortality between the two treatment groups (p = .02), indicating that radical prostatectomy reduced disease-related mortality in this sample. No significant differences in overall mortality between the samples were found.
Patients with a PSA DT value ≤ 3 years should be offered radical treatment for prostate cancer. The rest of the sample is being closely evaluated with frequent PSA screenings and periodic prostate rebiopsies. A majority of men remain on surveillance (n = 198), and the 8-year survival rate is currently 85% with a prostate cancer-specific survival rate of 99%.
Patients were likely to be 75 years of age or older and Caucasian, with lowstage and low-grade disease; 7% (23) of the men undergoing watchful waiting died during the study period, and 3 of those deaths were attributed to prostate cancer.
Men expressed feelings of anxiety, distress, fear, and anger. They reported thoughts of shock and disbelief and shared concerns about death and mortality. A third were concerned about possible side effects of treatment to include impotence.
At 44 months, 22 men had progressed; a second biopsy was the most significant factor for progression at 45 months (range = 7-84 months).
African American and Hispanic men were more likely to receive watchful waiting than were similar Caucasians.
Erectile dysfunction and urinary leakage had a higher incidence in radical prostatectomy patients. Urinary obstruction was higher in the watchful waiting group. No differences were observed on bowel function, anxiety, depression, wellbeing, or quality of life at an average follow-up of 4 years. (continued) watchful waiting in prostate cancer, including characteristics of men undergoing watchful waiting, clinical practice guidelines, mortality, uncertainty, and quality of life. These themes are used as a framework in the presentation of recent literature. Harlan et al. (2003) studied 402 men undergoing watchful waiting between the years 1989 and 2000 within the Cancer of the Prostate Strategic Urologic Research Endeavor national registry. The researchers reported that the use of watchful waiting increased by 2% between the years of 1989 and 1994. However, watchful waiting decreased 4% between 1994 and 2000 to an overall rate of 5.5% for all prostate cancer patients. Characteristics of men undergoing watchful waiting indicated that they were likely to have a low risk of morbidity and mortality from prostate cancer and were 75 years of age and older, White, less educated, and single. Men undergoing watchful waiting as a management option also tended to have Medicare as their primary form of insurance and several comorbidities. Shavers et al. (2004) , in a study analyzing the National Cancer Institute's Surveillance, Epidemiology, and End Results prostate cancer data from 1994 to 1996, revealed possible disproportions of African American men undergoing watchful waiting relative to their risk for the disease. In their analysis of 24,974 men with prostate cancer older than the age of 65 years in the National Cancer Institute's database, it was identified that 29% of African American men and 28.4% of Hispanic men received watchful waiting in comparison to 23% of White men. In controlling for several variables including clinical characteristics, prostate cancer stage, age, and life expectancy, it was determined that the two minority groups were significantly more likely to undergo watchful waiting than were their White counterparts. Overall, the use of watching and monitoring has decreased, and this decrease has been most notable in low-risk patients, that is, patients with PSA ≤ 10 ng/mL, Gleason score < 7 with no Pattern 4 or 5 disease on biopsy, and clinical stage T1 or T2a) (Cooperberg, Moul, & Carroll, 2005) .
Characteristics of Men Undergoing Watchful Waiting

Clinical Practice Guidelines
With the availability of multiple treatment options of prostate cancer and often similar outcomes, a substantial amount of controversy remains regarding the best treatment decision for any given set of patient and clinical parameters. The American Urological Association last published guidelines on the management of localized prostate cancer in 1995. More recently, the European Association of Urology (Aus et al., 2005) published treatment guidelines on prostate cancer treatment that are listed in Table 2 . Klotz (2005b) , in a review article discussing watchful waiting, stated that identifying men who are appropriate candidates for watchful waiting presents a challenge. Although a significant number of men may be suitable for this management option, related to the "indolent and slow growing" (p. 8165) nature of the disease, the number of men undergoing this management option is disproportionate to the indications. Klotz (2004 Klotz ( , 2005a Klotz ( , 2005c ) is currently investigating the use of estimated PSA doubling time (DT) as a criterion for decision making in a sample of 299 men with a median age of 70 years (range = 49-84 years). Participants within these studies have PSA values < 15, Gleason ≤ 7, and tumor stage ≤ 2b. Clinical indications for treatment with this approach indicated that patients with a PSA DT Author(s) and Year Wallace (2003) Protocol Language
Watchful waiting
Purpose To examine the impact of uncertainty on quality of life among older men undergoing watchful waiting for prostate cancer using Mishel's uncertainty in illness model.
Results
As uncertainty and the perception of danger increased, quality of life decreased. The combination of both uncertainty and danger perception explained a significant amount of variance in quality of life among this sample. value ≤ 3 years should be offered radical treatment for prostate cancer. The rest of the sample is being closely evaluated with frequent PSA screenings and periodic prostate rebiopsies. Thus, a majority of men remain on surveillance (n = 198 or 66%), and the 8-year survival rate is currently 85% with a prostate cancer-specific survival rate of 99%. Twelve percent of the men opted for aggressive intervention in the absence of disease progression (Klotz, 2006) .
Similarly, Eastham (2005) provided a review of the active surveillance literature and reported the difficulty in identifying the small number of men in need of aggressive treatment and sparing a majority the unwanted side effects of treatment. Active surveillance requires frequent PSA testing at 3month intervals during the first 12 months following diagnosis and then at 6-month intervals with digital rectal examination and repeat biopsies. Biopsies were considered most important, as PSA levels may not accurately represent disease progression. Patel et al. (2004) retrospectively evaluated the use of expectant management (active surveillance) with delayed treatment in a sample of 88 men with localized disease. The sample was composed of men who underwent expectant management between 1984 (prior to PSA testing) and 2001. PSA and digital rectal examination were evaluated every 3 months for the 1st year, and biopsy was recommended every 6 months; median follow-up was 44 months. Seventy men (80%) had repeat biopsies, and 22 (31%) had progressed. This second biopsy was the most significant factor for progression at 45 months (range = 7-84 months). Seven (10%) men without signs of progression opted for aggressive therapy because of increased anxiety, supporting the need for appropriate psychosocial intervention. Albertsen, Hanley, and Fine (2005) reviewed Connecticut Tumor Registry data of 767 men with localized prostate cancer undergoing watchful waiting and identified that the mortality rate was 33 men per 1,000 at 15 years and 18 deaths per 1,000 men after 15 years. Mortality in this study was linked with higher grade prostate cancers within 10 years of diagnosis. The study indicated no significant increase in mortality in men undergoing watchful waiting after the 15-year point. Holmberg et al. (2002) conducted a 10-year longitudinal study of 695 men with early-stage prostate cancer randomly assigned to watchful waiting (n = 348) or radical prostatectomy treatment groups (n = 347). There was a significant difference in prostate cancer mortality between the two treatment groups (p = .02), indicating that radical prostatectomy reduced disease-related mortality in this sample. There were no significant differences in overall mortality between the samples. In a further analysis of the same sample of 695 men undergoing watchful waiting (n = 348) or radical prostatectomy (n = 347), Bill-Axelson et al. to 2002. At 42 months, the median follow-up, 80% of the surveillance patients (n = 64) remained on observation, and 62% (n = 20) of the watchful waiting sample remained on observation. A total of 19 patients (17%; surveillance and watchful waiting) underwent more radical treatments such as radical prostatectomy, radiation treatment, or palliative hormone therapy. Eight patients (7%) died from diseases, and one patient (<1%) died from prostate cancer. Johansson et al. (2004) conducted a follow-up study of 223 men undergoing watchful waiting. In this sample of men with early-stage prostate cancer, the results identified that the cancer progressed slowly during the first 15 years of the disease. However, the prostate cancer-specific survival rate decreased from 78.7% of the sample at 15 years after diagnosis to 54.4% at 20 years, with a corresponding increase in mortality. The researchers concluded that prostate cancer may become problematic if a greater than 15-year survival is predicted. Wallace (2003) reported on a study of 19 men aged 65 to 85 years, undergoing the watchful waiting management option for prostate cancer. The study used Mishel's (1988) uncertainty in illness model as a framework for understanding the impact of uncertainty on quality of life. The findings from the descriptive study identified that as uncertainty and the perception of danger increased, quality of life decreased. The combination of both uncertainty and danger perception explained a significant amount of variance (60%) in quality of life among this sample: R 2 change = 0.209, F(3, 14) = 6.998, p = .004. Bailey, Mishel, Belyea, Stewart, and Mohler (2004) conducted the only study that tested the effects of an uncertainty management intervention on older men undergoing watchful waiting for prostate cancer. Watchful waiting participants were assigned to either an experimental (n = 21) or control group (n = 20). The results showed that men who received the intervention reported higher quality of life (p = .01) and less depression (p = .06). Moreover, the study provides essential information about the impact of uncertainty on quality of life and provides a framework for understanding watchful waiting within the reconceptualized uncertainty in illness model (Mishel, 1990) . Chapple et al. (2002) interviewed 50 men from England, Wales, and Scotland who had been diagnosed with and in some cases treated for prostate cancer. Four men (8%) underwent watchful waiting and described how they made the decision to evaluate their disease. They were aware of treatment side effects that could impair their quality of life and knew that aggressive therapy might not prolong their lives. One man was reassured after viewing an educational video that he could in the future receive treatment if and when needed and thus opted to watch and wait. However, the remaining 3 men (6%) reported feeling pressure from their families or support group members to initiate standard treatment. Many of the men who chose aggressive treatment did not remember their physicians discussing watchful waiting as an alternative to therapy. Hedestig, Sandman, and Widmark (2003) conducted a qualitative study of 7 Swedish men aged 62 to 69 years who were between 3 and 36 months from diagnosis. The interviews focused on two areas: patient experience at the time of diagnosis and the experience of being a patient with prostate cancer. Four themes emerged: "To be alone with the disease experience; A masculine experience; The physician-a companion; and To be uncertain, afraid and worried" (Hedestig et al., 2003, pp. 57-58) . Men described physician visits fraught with uncertainty and a constant worry of disease progression. Living with untreated prostate cancer was described as "living life under a dark shadow that was a threat to life" (Hedestig et al., 2003, p. 58) .
Mortality
Uncertainty and Quality of Life
Similarly, Bailey et al. (in press ) conducted a qualitative study of 10 men aged 64 to 88 years who were within 12 months of their prostate cancer diagnosis and had selected watchful waiting. Mishel's (1990) reconceptualized theory of uncertainty in illness was used to organize the findings, and three themes emerged: uncertainty, appraisal of danger, and appraisal of opportunity. Uncertainty resulted from a lack of symptoms, diagnostic testing, and the issue of treatment. Their disease was difficult to self-monitor, and uncertainty stemmed from the limited signals men had to signify progression. Danger resulted from the many alternatives and the lack of clear guidelines on appropriateness of treatment. They worried that getting a second opinion would add to their conflict about the decision to watch and wait. Finally, several of the men saw the decision to watch and wait as an opportunity to successfully manage their uncertainty through work, self-care, keeping options open, and the use of alternative medications and prayer.
In a subsample of men enrolled in a clinical intervention trial, Kronenwetter et al. (2005) interviewed 26 participants who had elected watchful waiting. Twenty (77%) of these newly diagnosed men described their experiences using the emotion-laden terms anxiety, upset, distress, fear, and anger. Sixteen (62%) men reported thoughts of shock and disbelief, and 15 (58%) men shared their concerns about death and mortality. Nearly a third (8 or 31%) of the men expressed concerns regarding possible side effects of treatment to include impotence, seen widely in the literature as having a negative effect on quality of life.
In a study of 326 Swedish men aged 48 to 74 years undergoing watchful waiting (n = 187) or radical prostatectomy (n = 189), Steineck et al. (2002) measured several quality of life outcomes of the two groups of prostate cancer patients. The researchers reported a higher incidence of both erectile dysfunction (80% vs. 45%) and urinary leakage (49% vs. 21%) in radical prostatectomy patients compared to the men in watchful waiting. However, urinary obstruction was higher in the watchful waiting group (44% vs. 28%). No significant differences were seen between the two groups on bowel function, anxiety and depression, well-being, and quality of life. A total of 26% of both groups reported bowel-related problems, 9% of radical prostatectomy and 10% of watchful waiting participants reported high anxiety, 7% of radical prostatectomy and 11% of watchful waiting participants reported high levels of depression, 35% of radical prostatectomy and 36% of watchful waiting participants reported low or moderate well-being, and 40% of radical prostatectomy and 45% of watchful waiting participants reported low or moderate quality of life.
Discussion
Clearly there is conflicting evidence that forces men with prostate cancer and their health care providers to consider the option of watchful waiting for the management of prostate cancer with caution. The original study by Johansson et al. (1992) supported the watchful waiting option with positive 10-year survival data. A more recent 20-year follow-up of the same 223 participants was not clearly as optimistic and indicated substantial increases in mortality among the 49 men who were still alive more than 15 years after diagnosis (Johansson et al., 2004) . However, the 2005 study by Albertsen et al. that also included 20-year data indicated that the mortality rate from prostate cancer appears to remain stable after 15 years of diagnosis, supporting the watchful waiting management for prostate cancer when clinical indications are present.
Although watchful waiting is an active, responsible approach to the management of a slow-growing cancer in a nonessential organ, it conflicts with American values that call for the use of all and any available treatments to eradicate disease among older adults (Kaufman, Shim, & Russ, 2004) . The dwindling numbers of men undergoing watchful waiting for prostate cancer are clearly evident in the difficulty of recruiting research participants to further explore the experience and outcomes of men undergoing this management option. Although there are very few researchers investigating watchful waiting, difficulty in participant recruitment is widely experienced, which further adds to the lack of knowledge regarding the watchful waiting management option for prostate cancer and renders watchful waiting a more unreasonable alternative.
The available evidence regarding watchful waiting supports that this management option results in considerable uncertainty among older men with the disease. Wallace (2003) reported that as uncertainty and the perception of danger increased among men with prostate cancer, affective health-related quality of life was reduced. Bailey et al. (in press) reported three domains in the data-uncertainty about disease and treatment, appraisal of danger as a result of trying to make the best decision regarding treatment, and appraisal of opportunity in which men learned to manage their uncertainty-in a sample of 10 older men undergoing watchful waiting. Each domain was supported by categories describing the experience of men undergoing watchful waiting as an alternative to treatment for prostate cancer.
Although these descriptive studies were conducted with low numbers, they are the few available that document the experience of men undergoing watchful waiting for the management of prostate cancer. Moreover, the lack of research participants has hampered interventional studies, leaving clinicians with inadequate results and little if any evidence to support watchful waiting for U.S. older men with prostate cancer. In the only psychointerventional study conducted on men undergoing watchful waiting for prostate cancer, Bailey et al. (2004) identified that men who received the intervention came to see their lives in a new light, reduced their depressive symptoms, and reported higher quality of life. As the only psychointerventional study of the watchful waiting management option among men with prostate cancer, these results are promising and should be used to support further study.
A further compounding factor toward the disuse of watchful waiting as a management option for prostate cancer is the increasing technology available to treat prostate cancer and the diminishing side effects of prostate cancer therapy. When watchful waiting first began its use as a reasonable option for the management of prostate cancer, support for this option primarily focused on its benefits, namely, avoiding the side effects of radical prostatectomy and radiation therapy. Recently, Incrocci (2005) reported that the rates of impotence following radical prostatectomy range between 7% and 72% and between 5% and 51% following brachytherapy. These results must be interpreted cautiously, as statistics are complicated by preexisting erectile dysfunction prior to treatment for prostate cancer and failure to report erectile dysfunction. The rate of urinary incontinence is approximately 25% (Heidenreich, Ohlmann, Ozgur, & Engelmann, 2006) . The rate of rectal discomfort following radiation is approximately 39% (Heidenreich et al., 2006) , with Putta and Andreyev (2005) reporting fecal incontinence between 8% and 56%. With the emergence of oral erectile agents and nerve-sparing procedures, these treatments have resulted in reduced morbidity among older men and are more viable than in the past, further decreasing the benefits of watchful waiting.
Despite these seemingly pessimistic indications toward watchful waiting, there are several considerations on the other side. First and foremost, the anatomy of the body is not likely to change in the near future. Consequently, prostate cancer will remain a slow-growing tumor in a nonessential organ. This leaves the clinical indications for watchful waiting reported by Wallace et al. (2004) and Warlick et al. (2006) the same. Men with a life expectancy of 10 years or less due to illness or advanced age, Gleason scores < 7, low PSA density and velocity, and organconfined disease (National Comprehensive Cancer Network, 2002) are still good candidates for watchful waiting, despite the availability of other treatments. This is of course provided that the watchful waiting management option is not considered a death sentence to the patients and viewed as a cost-effective opportunity to avoid surgery and radiation. Further interventional studies are clearly needed to provide the evidence to support this change in perception.
Another fact that is clearly not going to change is the rising older adult population. Currently, the health care system is managing a graying of America, and the United States is in the midst of an unprecedented population shift. Through the development of new technology and greater emphasis on health promotion, the population of older adults can be expected to live an average of 18 more years than they did 100 years ago, for a total of 83 years. In the year 2003, there were approximately 36 million people age 65 years and older residing in the United States, representing approximately 12% of the total population (Administration on Aging, 2004). Moreover, the incidence of prostate cancer increased greatly with the development of PSA to detect the disease. Although numbers have equalized, the growing elderly population in the United States will likely continue to make prostate cancer the number one cancer among older men, further mandating watchful waiting as a management alternative and keeping prostate cancer as a priority for research funding.
With both negative and positive indications toward watchful waiting, where does this management option stand? Will watchful waiting drop off as a reasonable management option for prostate cancer? Are the few men who continue to use watchful waiting deserving of further descriptive and interventional studies regarding this management option? If so, who will do it, and how will it be funded? These are all important questions for the health care community and watchful waiting researchers to consider and may be best viewed within the uncertainty in illness model developed by Mishel (1988) and reconceptualized in 1990. Within this model, watchful waiting is not viewed as a "do nothing" approach to the management of prostate cancer or a "death sentence" as perceived by men undergoing this management option. Rather, watchful waiting is approached as an opportunity to improve health and advance quality of life. This model provides the best opportunity to continue to support watchful waiting despite the perceptions of men with prostate cancer and the increasing technology that directs men and their health care providers away from watchful waiting as a management option for the disease. Within the model, Mishel (1990) suggested that if the uncertainty of illness can be framed as a usual event, it becomes positive and enables patients to see life's possibilities. The model provides a framework for research to further describe the experience of watchful waiting and provides direction for interventions to reduce documented uncertainty associated with the management option. The model was tested in a sample of 39 older men undergoing watchful waiting. Results indicated that compared to controls, men in the experimental group came to see their lives in a new way, reduced their depressive symptoms, and reported higher quality of life. Moreover, the model changes the view of prostate cancer from an acute to a chronic illness . In an editorial by Wallace (2001) , this change in paradigm for prostate cancer was first discussed and continues to be a direction for future consideration of prostate cancer and other diseases once considered acute among older adults and now functioning as chronic illness.
The availability of the model keeps watchful waiting as a management option for prostate cancer but is useless unless further watchful waiting research participants can be actively involved in studies using this framework. This is unlikely given the difficulty over the past 5 years in participant recruitment for watchful waiting studies. The best hope of testing this model may lie in the expansion of the concept of watchful waiting toward other diseases that affect older adults. Watchful waiting is a viable management option for older adults with prostate cancer as well as a number of other diseases in the elderly, such as depression, lung cancer, HIV, unstable angina and coronary artery disease, benign prostatic hypertrophy, problematic menopause, anticoagulation disorders, and more recently chronic hepatitis C. The review of literature reveals several themes surrounding the experience of watchful waiting, including the use and availability in certain age groups and the perception of this management option among patients and family members. A multidisease study using the reconceptualized model of uncertainty will provide both descriptive and interventional information regarding the experience of watchful waiting as a management approach for prostate cancer, as well as for other chronic illnesses. Within this approach, information may become known that encourages the selection of watchful waiting as a more viable consideration for prostate cancer and other chronic illnesses among older adults that were once considered acute but are now chronic as the technology and life span continue to expand.
